Daniel Kwame Afriyie1, Seth Kwabena Amponsah2, Justice Dogbey3, Kwabena Agyekum1, Samuel Kesse1, Ilse Truter4, Johanna C Meyer5, Brian Godman6,7,8. 1. a Pharmacy Department , Ghana Police Hospital , Accra , Ghana. 2. b Department of Pharmacology and Toxicology , University of Ghana School of Pharmacy , Legon , Ghana. 3. c Plastics and Burns Unit, Pharmacy Department , Korle-Bu Teaching Hospital , Accra , Ghana. 4. d Drug Utilization Research Unit (DURU), Department of Pharmacy , Nelson Mandela Metropolitan University , Port Elizabeth , South Africa. 5. e School of Pharmacy , Sefako Makgatho Health Sciences University , Pretoria , South Africa. 6. f Department of Clinical Pharmacology , Karolinska Institutet , Stockholm , Sweden. 7. g Strathclyde Institute of Pharmacy and Biomedical Sciences , Strathclyde University , Glasgow , UK. 8. h Health Economics Centre , Liverpool University Management School , Liverpool , UK.
Abstract
BACKGROUND AND OBJECTIVES: Widespread empiric use of antibiotics exists especially in developing countries. This is a concern since inappropriate use of antibiotics, including their extended inappropriate use, will increase resistance rates. Consequently, there is a need to evaluate antibiotic utilisation across healthcare sectors to improve future use. This includes ceftriaxone, widely used among hospitals including those in Ghana. METHODS: A cross-sectional study to evaluate the appropriateness of ceftriaxone prescribing in a leading hospital in Ghana. Ceftriaxone prescribing in patient-record cards was assessed using a modified WHO drug-utilization evaluation criteria as well as referencing the national standard treatment guidelines in Ghana and the ceftriaxone package insert. RESULTS: A total of 251 patients were assessed. Ceftriaxone was most commonly prescribed for comorbid malaria with bacterial infections, urinary tract infections, sepsis and gastroenteritis. The appropriateness of the indication was 86% (n = 218). The doses most prescribed were 1g (41%) and 2g (39%). Stat dose and once-daily dosage regimen constituted 51.4% and 84.5%, respectively. The most common duration of treatment was 1 (51.4%) and 2 days (35.1%). The overall appropriateness of prescribing was 93% against a pre-set threshold of 97%. CONCLUSION: The appropriateness of ceftriaxone prescribing was high in this leading hospital in Ghana; however, there is room for improvement with targeted education initiatives, with further research planned.
BACKGROUND AND OBJECTIVES: Widespread empiric use of antibiotics exists especially in developing countries. This is a concern since inappropriate use of antibiotics, including their extended inappropriate use, will increase resistance rates. Consequently, there is a need to evaluate antibiotic utilisation across healthcare sectors to improve future use. This includes ceftriaxone, widely used among hospitals including those in Ghana. METHODS: A cross-sectional study to evaluate the appropriateness of ceftriaxone prescribing in a leading hospital in Ghana. Ceftriaxone prescribing in patient-record cards was assessed using a modified WHO drug-utilization evaluation criteria as well as referencing the national standard treatment guidelines in Ghana and the ceftriaxone package insert. RESULTS: A total of 251 patients were assessed. Ceftriaxone was most commonly prescribed for comorbid malaria with bacterial infections, urinary tract infections, sepsis and gastroenteritis. The appropriateness of the indication was 86% (n = 218). The doses most prescribed were 1g (41%) and 2g (39%). Stat dose and once-daily dosage regimen constituted 51.4% and 84.5%, respectively. The most common duration of treatment was 1 (51.4%) and 2 days (35.1%). The overall appropriateness of prescribing was 93% against a pre-set threshold of 97%. CONCLUSION: The appropriateness of ceftriaxone prescribing was high in this leading hospital in Ghana; however, there is room for improvement with targeted education initiatives, with further research planned.
Entities:
Keywords:
Appropriateness; Ghana; ceftriaxone; drug use evaluation; thresholds
Authors: Pius G Horumpende; Stephen E Mshana; Elise F Mouw; Blandina T Mmbaga; Jaffu O Chilongola; Quirijn de Mast Journal: Antimicrob Resist Infect Control Date: 2020-09-07 Impact factor: 4.887
Authors: Eneyi E Kpokiri; Misha Ladva; Cornelius C Dodoo; Emmanuel Orman; Thelma Alalbila Aku; Adelaide Mensah; Jonathan Jato; Kwadwo A Mfoafo; Isaac Folitse; Araba Hutton-Nyameaye; Inemesit Okon-Ben; Paapa Mensah-Kane; Emmanuel Sarkodie; Benedict Awadzi; Yogini H Jani Journal: Antibiotics (Basel) Date: 2021-12-22
Authors: Daniel Kwame Afriyie; Israel A Sefah; Jacqueline Sneddon; William Malcolm; Rachel McKinney; Lesley Cooper; Amanj Kurdi; Brian Godman; R Andrew Seaton Journal: JAC Antimicrob Resist Date: 2020-02-18